Introduction
============

A number of female reproductive system diseases such as repeated implantation failure, preeclampsia, endometriosis, reproductive system malignancy and breast cancer lack tools for early diagnosis. Although clinical biomarkers such as squamous cell carcinoma antigen and CA125/199 can be used in the diagnosis of female reproductive tract tumors, they are of low sensitivity and specificity ([@b1-br-0-0-1278],[@b2-br-0-0-1278]). Therefore, new effective biomarkers are urgently needed for the diagnosis of these conditions.

Non-coding RNAs have been extensively used in clinical experiments and are of great potential as biomarkers for detection of disease ([@b3-br-0-0-1278]). Circular RNAs (circRNAs) are a class of endogenous non-coding RNA and consist of a covalently closed continuous loop with neither 5\'-3\' polarity nor a polyadenylated tail ([@b4-br-0-0-1278],[@b5-br-0-0-1278]). Unlike linear RNAs, circRNAs are protected against the effects of RNA enzymes due to their lack of free ends; these molecules are thus more stable compared with linear RNAs ([@b5-br-0-0-1278]). With the development of RNA-seq analysis and bioinformatics technologies, recent studies have reported the use of circRNAs in the early detection and prognosis of certain types of cancer, such as gastric cancer ([@b6-br-0-0-1278]), hepatocellular carcinoma ([@b7-br-0-0-1278]), lung cancer ([@b8-br-0-0-1278]), cervical squamous cell carcinoma (CSCC) and breast cancer (BRCA) ([@b9-br-0-0-1278]), as well as a number of female reproductive system diseases including repeated implantation failure ([@b10-br-0-0-1278]), preeclampsia ([@b11-br-0-0-1278]) and ovarian endometriosis ([@b12-br-0-0-1278]). Considering the association between hormone-responsive BRCA and the female reproductive system ([@b13-br-0-0-1278]), this condition was included as a female reproductive system disease in the present meta-analysis.

The aim of this meta-analysis was to summarize all circRNAs that have been investigated as diagnostic markers for female reproductive system diseases and to review their efficiency as novel diagnostic biomarkers in such diseases. Available data from published literature were evaluated to determine if circRNAs may be used as sensitive and specific molecular biomarkers.

Materials amd methods
=====================

### Search strategy

This systematic meta-analysis was performed in strict accordance with the guidelines for diagnostic meta-analysis. Eligible studies published on PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>), EMBASE (<https://embase.com/>), Web of Science (<https://www.isiknowledge.com/>) and Cochrane Library (<https://www.cochranelibrary.com/>) before February 20, 2019 were selected for meta-analysis. Only studies published in English were included. No restrictions were applied for the year of publication or publication status. Databases were search using the following keywords: 'Circular RNA' OR 'circRNA' AND 'endometrial' OR 'endometrium' OR 'ovarian' OR 'ovary' OR 'cervical' OR 'uterine' OR 'uterus' OR 'uterine cervix' OR 'breast' OR 'vagina\*' OR 'pregnancy' OR 'pre-eclampsia' OR 'PCOS' OR 'placenta previa' OR 'gynaecology' OR 'obstetrics' OR 'genitalia', and 'diagnosis' OR 'diagnostic' OR 'sensitivity' OR 'specificity' OR 'receiver operating characteristic curve' OR 'ROC' OR 'AUC\'.

### Selection of publications

Two researchers independently reviewed all search results based on the titles and abstracts; the relevant studies were included in the full text review. Data extraction was performed by other researchers. Any disagreement regarding the inclusion or exclusion of studies were resolved by discussion involving a third investigator. All studies included in the meta-analysis met the following criteria: i) Studies that reported on the diagnostic value of circRNAs for any female reproductive system diseases type; ii) studies which contained sample, sensitivity, specificity and AUC data; and iii) studies that enrolled \>30 cases and matched controls. Studies were excluded as follows: i) Duplicate studies; ii) reviews, letters, conference abstracts, case reports and articles with insufficient data; iii) articles studying circRNA in cell lines; and iv) articles published in languages other than English.

### Data extraction and quality assessment

The following parameters were obtained from all studies: First author name, publication year, study area, patient ethnicity, disease type, specimen, sample size, as well as data on circRNA sensitivity and specificity. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool ([@b14-br-0-0-1278]) was used to perform quality assessment of each included study.

### Statistical analysis

All statistical analyses were conducted using the analytical software RevMan5.3 (The Cochrane Collaboration) and STATA14.2 (StataCorp LLC). All data such as the number of true positives (TP), false positives (FP), true negatives (TN) and false negatives (FN) were extracted from each study to calculate the pooled sensitivity and specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and their 95% confidence intervals (CI), summary receiver operator characteristic (sROC) curve and area under the curve (AUC). The data obtained was used to determine the overall performance of circRNAs in identifying female reproductive system diseases. P\<0.05 was considered to indicate a statistically significant difference. In addition, heterogeneity across studies was determined using Cochran\'s Q and I^2^ statistics, where I^2^\>50% indicated the existence of significant heterogeneity. Meta-regression analysis was utilized to detect the possible sources of heterogeneity.

Results
=======

### Literature search

A total of 163 potentially eligible articles were reviewed in this meta-analysis. The literature search strategy is depicted as a flow chart in [Fig. 1](#f1-br-0-0-1278){ref-type="fig"}. Among the 163 studies, 37 were duplicates and 22 were reviews, letters or conference abstracts. Following screening the titles and abstracts of the remaining publications, 70 were identified not to be relevant to the present study. A total of 34 articles were eligible for full-text review, and 28 articles were excluded due to incomplete full-texts or incomplete data. Finally, six eligible studies (each circRNA as a test, a total of 15 tests) were included in the meta-analysis ([@b15-br-0-0-1278]).

### Study characteristics

The characteristics of the six included studies with 15 tests are summarized in [Table I](#tI-br-0-0-1278){ref-type="table"}: A total of 613 individuals representing three types of disease were enrolled in the selected studies. These studies were of high quality based on the QUADAS-2 analysis ([Fig. 2](#f2-br-0-0-1278){ref-type="fig"}).

### Meta-analysis

Overall, the detection performance of circRNAs was as follows: The pooled sensitivity was 0.70 (95% CI, 0.64-0.76; Q=47.41; P\<0.001; I^2^=70.47%) and the pooled specificity was 0.70 (95% CI, 0.64-0.75; Q=35.07; P\<0.001; I^2^=60.08%). The PLR and NLR were 2.33 (Q=47.44; P=0.001; I^2^=54.95%) and 0.42 (95% CI, 0.33-0.54; Q=55.70; P\<0.001; I^2^=74.87%), respectively, and the diagnostic score was 1.70 (Q=60.49; P\<0.001; I^2^=76.86%). The pooled DOR was 5.48 (Q=2.5x10^7^; P\<0.001; I^2^=100.00%). Additionally, the AUC of the sROC curve was 0.76 (95% CI, 0.72-0.79). The relevant forest plots and sROC are presented in [Fig. 3](#f3-br-0-0-1278){ref-type="fig"}.

### Meta-regression analyses

A meta-regression based on disease type (benign or malignant) and sample size (\>100 or ≤100) was used to identify the possible sources of heterogeneity. The results of the meta-regression analysis of probable factors suggested that different sample sizes may increase heterogeneity in pooled sensitivity (P=0.02), and disease types may result in heterogeneity in pooled specificity (P=0.04) ([Table II](#tII-br-0-0-1278){ref-type="table"}). The bivariate boxplot demonstrates the heterogeneity of each study ([Fig. 4](#f4-br-0-0-1278){ref-type="fig"}). Two tests not included in the boxplot belonged study no. 6 (CSCC group). After excluding this study, Cochran\'s Q and I^2^ were decreased in the resultant forest plot, which was indicative of improvement in homogeneity. However, the sensitivity decreased from 0.70 to 0.68, specificity decreased from 0.70 to 0.66, PLR decreased from 2.33 to 2.20, NLR increased from 0.42 to 0.48 and sROC decreased from 0.76 to 071 ([Fig. 5](#f5-br-0-0-1278){ref-type="fig"}). This reduction suggested that study 6 (CSCC group) had high sensitivity and specificity compared with the other studies.

Discussion
==========

CircRNA is a novel category of non-coding RNAs with a closed circular structure. These specialized structures make circular RNAs more stable than linear RNAs due to their resistance to RNA enzymes such as exonuclease and ribonuclease ([@b5-br-0-0-1278]). A previous study has demonstrated that the half-life of mRNAs is only about 10 h, whereas whole circRNAs have a half-life \>48 h ([@b20-br-0-0-1278]). CircRNAs are highly abundant in various human tissues and cell samples and exhibit highly tissue-specific expression, especially in hepatocellular, cervical and ovarian carcinoma ([@b21-br-0-0-1278],[@b22-br-0-0-1278]). For these reasons, circRNA are excellent candidate biomarkers for diagnosing human diseases.

In the present meta-analysis, relevant articles were screened across four databases, and six relevant studies were finally included to evaluate the diagnostic value of circRNAs in diseases of the female reproductive system. To the best of our knowledge, this is the first meta-analysis performed on this topic. The pooled sensitivity and specificity were 0.70 and 0.70, respectively, indicating that circRNAs may be valid diagnostic markers in female reproductive system diseases. The pooled DOR was 5.48, and the AUC of the sROC curve was 0.76. These results demonstrated that circRNAs exhibited a moderate diagnostic performance. Similarly, circRNAs have been reported to possess prognostic value for female reproductive system tumors, such as endometrial and epithelial ovarian cancer ([@b23-br-0-0-1278],[@b24-br-0-0-1278]), but no specific diagnostic data was available. Overall, circRNAs may be appropriate for use as diagnostic biomarkers in female reproductive system diseases.

However, it should be highlighted that heterogeneity was present in the current pooled estimates, as the included studies involved experiments which used whole blood, plasma or tissues. A meta-regression based on disease type and sample size was performed; the results demonstrated that the heterogeneity may arise from the sample size and disease type. The bivariate boxplot demonstrated that study no. 6 (regarding CSCC) was the source of heterogeneity. Exclusion of this study resulted in decreased Q and I^2^ values, both of which are indicators of disease heterogeneity. Study no. 6 was the only study on cervical cancer which utilized whole blood, which may have been the source of heterogeneity.

The limitations of this meta-analysis should be taken into consideration. Firstly, all included studies were authored by Chinese investigators and were on ethnic Chinese patient samples. Therefore, the overall diagnostic accuracy of circRNAs may be not be applicable to the general population; future research regarding circRNAs as biomarkers should be expanded to multiple countries and ethnicities. Next, the enrolled studies only included data on those with preeclampsia, CSCC and BRCA. There are several other female reproductive system diseases that lack early diagnostic tools including repeated implantation failure and reproductive system malignancy such as ovarian cancer, the 5-year survival rate of which is only 30% as a vast majority of patients present with widespread metastasis ([@b25-br-0-0-1278],[@b26-br-0-0-1278]). The lack of an effective molecular biomarker for diagnosing early stage ovarian cancer is a key contributor to its overall poor prognosis ([@b27-br-0-0-1278]). Lastly, tissue-extracted circRNAs may not be the ideal biomarker considering that circRNAs are also stable and abundant in exosomes ([@b28-br-0-0-1278],[@b29-br-0-0-1278]). The detection of circRNAs from exosomes in plasma or serum may be a better alternative in diagnosing disease. The results of the present meta-analysis suggested that circRNAs may serve as a useful, noninvasive molecular biomarker for clinical practice in the future. More extensive studies are urgently needed to evaluate the diagnostic performance of plasma or serum circRNAs in the context of female reproductive system diseases.

In conclusion, circRNAs possess the potential to function as diagnostic biomarkers for female reproductive system diseases. Additional large-scale studies are required to verify the results of this preliminary study.
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###### 

Characteristics of the included studies.

  Test (study) no.   Author                Disease type   CircRNA            Specimen        SEN    SPE    TP   FP   FN   TN   Patients, n   Controls, n   Expression   (Refs.)
  ------------------ --------------------- -------------- ------------------ --------------- ------ ------ ---- ---- ---- ---- ------------- ------------- ------------ ----------------------
  1(1)               Lü *et al*, 2017      BRCA           hsa_circ_103110    Tissue          0.63   0.63   32   19   19   32   51            51            Down         ([@b20-br-0-0-1278])
  2(1)               Lü *et al*, 2017      BRCA           hsa_circ_104689    Tissue          0.57   0.55   29   23   22   28   51            51            Down         ([@b20-br-0-0-1278])
  3(1)               Lü *et al*, 2017      BRCA           hsa_circ_104821    Tissue          0.57   0.57   29   22   22   29   51            51            Down         ([@b20-br-0-0-1278])
  4(1)               Lü *et al*, 2017      BRCA           hsa_circ_006054    Tissue          0.65   0.69   33   16   18   35   51            51            Up           ([@b20-br-0-0-1278])
  5(1)               Lü *et al*, 2017      BRCA           hsa_circ_100219    Tissue          0.69   0.71   35   15   16   36   51            51            Up           ([@b20-br-0-0-1278])
  6(1)               Lü *et al*, 2017      BRCA           hsa_circ_406697    Tissue          0.63   0.63   32   19   19   32   51            51            Up           ([@b20-br-0-0-1278])
  7(2)               Yin *et al*, 2017     BRCA           hsa_circ_0001785   Plasma          0.79   0.76   45   4    12   13   57            17            Up           ([@b19-br-0-0-1278])
  8(2)               Yin *et al*, 2017     BRCA           hsa_circ_0108942   Plasma          0.82   0.50   45   8    12   9    57            17            Up           ([@b19-br-0-0-1278])
  9(2)               Yin *et al*, 2017     BRCA           hsa_circ_0068033   Plasma          0.73   0.58   45   7    12   10   57            17            Up           ([@b19-br-0-0-1278])
  10(3)              Jiang *et al*, 2018   Preeclampsia   hsa_circ_0001855   Plasma          0.53   0.70   19   11   16   24   35            35            Up           ([@b18-br-0-0-1278])
  11(3)              Jiang *et al*, 2018   Preeclampsia   hsa_circ_0004904   Plasma          0.53   0.70   19   11   16   24   35            35            Up           ([@b18-br-0-0-1278])
  12(4)              Hu *et al*, 2018      Preeclampsia   hsa_circ_0036877   Tissue/plasma   0.85   0.73   34   31   6    85   40            116           Down         ([@b17-br-0-0-1278])
  13(5)              Bai *et al*, 2018     Preeclampsia   hsa_circ_0007121   Tissue/plasma   0.77   0.70   23   12   7    29   30            41            Down         ([@b16-br-0-0-1278])
  14(6)              Wang *et al*, 2017    CSCC           hsa_circ_0101996   Whole blood     0.90   0.83   78   9    9    46   87            55            Up           ([@b15-br-0-0-1278])
  15(6)              Wang *et al*, 2017    CSCC           hsa_circ_0101119   Whole blood     0.70   0.93   61   4    26   51   87            55            Up           ([@b15-br-0-0-1278])

SEN, sensitivity; SPE, specificity; TP, true positives; FP, false positives; TN, true negatives; FN, false negatives; BRCA, breast cancer; CSCC, cervical squamous cell carcinoma; RT-qPCR, reverse transcription-quantitative PCR.

###### 

Meta-regression analysis.

  Parameter      Category        No. of studies   Sensitivity (95% CI)   P1                                                  Specificity (95% CI)   P2
  -------------- --------------- ---------------- ---------------------- --------------------------------------------------- ---------------------- ---------------------------------------------------
  Disease type   Malignant       11               0.71 (0.64-0.78)       0.17                                                0.70 (0.63-0.76)       0.04^[a](#tfn1-br-0-0-1278){ref-type="table-fn"}^
                 Benign          4                0.68 (0.56-0.81)                                                           0.70 (0.60-0.80)        
  Sample size    ≥100 samples    9                0.70 (0.62-0.77)       0.02^[a](#tfn1-br-0-0-1278){ref-type="table-fn"}^   0.70 (0.64-0.77)       0.08
                 \<100 samples   6                0.72 (0.63-0.81)                                                           0.68 (0.58-0.78)        

^a^P\<0.05. P1, sensitivity P-value; P2, specificity P-value.
